I.R.N. Verly

Catecholamines profiles at diagnosis: Increased diagnostic sensitivity and correlation with biological and clinical features in neuroblastoma patients

I.R.N. Verly, André B. P. Kuilenburg, N. G. G. M. Abeling et al. · European Journal of Cancer · 2017 · 73 citations

Neuro-oncology, Neuroblastoma Patients, Neuroblasts +6

mi<scp>R</scp> expression profiling at diagnosis predicts relapse in pediatric precursor <scp>B</scp>‐cell acute lymphoblastic leukemia

Smadar Avigad, I.R.N. Verly, Asaf Lebel et al. · Genes Chromosomes and Cancer · 2015 · 44 citations

Catecholamine excretion profiles identify clinical subgroups of neuroblastoma patients

I.R.N. Verly, René Leen, J.R. Meinsma et al. · European Journal of Cancer · 2019 · 24 citations

Neuro-oncology, Catecholamine Excretion Profiles, Neuroendocrine Disorder +4

Hypermethylated <i>RASSF1A</i> as Circulating Tumor DNA Marker for Disease Monitoring in Neuroblastoma

Lieke M. J. van Zogchel, Esther M. van Wezel, Jalenka van Wijk et al. · JCO Precision Oncology · 2020 · 23 citations · Full text

3-Methoxytyramine: An independent prognostic biomarker that associates with high-risk disease and poor clinical outcome in neuroblastoma patients

I.R.N. Verly, André B. P. Kuilenburg, N. G. G. M. Abeling et al. · European Journal of Cancer · 2017 · 22 citations

Neuroblastoma Patients, Medicine, Poor Clinical Outcome +6